### Abstract

Clozapine is associated with haematological abnormalities, with neutropenia and agranulocytosis of most concern. Granulocyte colony-stimulating factor (G-CSF) has been used to support clozapine rechallenge following neutropenia with the aim of maintaining the neutrophil count. This study aims to explore the practice, use, safety and efficacy of G-CSF in this context.

**Methods/Procedures**

We conducted a systematic review to identify all studies investigating or describing G-CSF as a prophylaxis to enable continued clozapine treatment during a rechallenge.

**Findings/Results**

We identified 32 reports of patients who received G-CSF either regularly (n = 23), or as required (n = 9) to support clozapine rechallenge following an episode of neutropenia necessitating discontinuation of clozapine. Seventy-five percent (n=24) of published cases remained on clozapine with the use of continual prophylactic G-CSF or after single G-CSF administrations (N=8). Seventy percent (n=16) of cases in receipt of continual prophylactic G-CSF were successfully maintained on clozapine. However, one of the three episodes of rechallenge in those with a history of severe agranulocytosis (ANC <0.1x10^9/L) had a recurrence of agranulocytosis at week 9.

**Implications/Conclusions**

Our findings suggest that GCSF can sometimes be safely used to support the rechallenge of clozapine. Further research is needed to confirm the safety and efficacy of G-CSF in this context.
maintenance of normal neutrophil counts and clozapine use post-neutropenia. Publication bias is an important limitation, however. Also, few reports clearly documented the presence or absence of an independent non-clozapine cause of the index neutropenia, which may have increased success rates. Furthermore, adverse events were not systematically recorded. Prospective studies are needed to determine safety, as if agranulocytosis occurs on clozapine while supported by G-CSF, there is no obvious alternate rescue therapy to promote granulopoiesis. From the available data, it is not possible to recommend this course of action for someone with a true clozapine agranulocytosis.
The use of G-CSF in clozapine rechallenge: a systematic review

John Lally1,2, Steffi Malik3, Amir Krivoy1,4, Eromona Whiskey4,5, David M Taylor4,6, Fiona P Gaughran1,4, Robert J Flanagan1, Aleksandar Mijovic7, James H MacCabe1,4

1 Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
2 Department of Psychiatry, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland
3 Medical School, University of Bristol, Bristol, UK
4 National Psychosis Service, South London and Maudsley NHS Foundation Trust, London, UK
5 Pharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK
6 London and Institute of Pharmaceutical Science, King’s College London, London, UK
7 Department of Haematological Medicine, King’s College Hospital, London, UK

Dr John Lally MB MSc MRCPsych,
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK and Senior Clinical Lecturer, Department of Psychiatry, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland.

Ms Steffi Malik MSc
MBChB student, University of Bristol Senate House, Tyndall Ave, Bristol, UK.
Department of Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK

Dr Amir Krivoy, MD
Clinical Research Worker, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London and National Psychosis Service, South London and Maudsley NHS Foundation Trust, London, UK

Dr Eromona Whiskey, MPharm
Pharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK; National Psychosis Service, South London and Maudsley NHS Foundation Trust, London, UK
Prof David M Taylor, BSc MSc PhD FFRPS, FRPharmS, Professor of Psychopharmacology,
Pharmacy Department, Maudsley Hospital, Denmark Hill, South London and Maudsley NHS
Foundation Trust and London and Institute of Pharmaceutical Science, King’s College
London, London, UK

Dr Fiona Gaughran MD, FRCPI, FRCP, FRCPsych,
Lead Consultant Psychiatrist, National Psychosis Service, South London and Maudsley NHS
Foundation Trust; Reader in Psychopharmacology and Physical Health, Institute of
Psychiatry, Psychology and Neuroscience, Kings College, London, UK;

Prof Robert J Flanagan, PhD, FRCPsych. Department of Psychosis Studies, Institute of
Psychiatry, Psychology and Neuroscience, King’s College London, London, UK

Dr Aleksandar Mijovic, MBBS, PhD, FRCPsych
Consultant Haematologist, Department of Haematological Medicine, King’s College Hospital,
London, UK

Dr James H MacCabe BSc MBBS FRCPsych MSc PhD
Reader in the Epidemiology of Psychosis, Department of Psychosis Studies, Institute of
Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London and Honorary
Consultant Psychiatrist, National Psychosis Service, South London and Maudsley NHS
Foundation Trust, London, UK

Corresponding author:
Dr John Lally
PO63, Department of Psychosis Studies
Institute of Psychiatry, Psychology and Neuroscience (IoPPN),
King’s College London,
De Crespigny Park
London SE5 8AF
Email: john.lally@kcl.ac.uk
Tel: (0044) (0)203 2286000
Fax:(0044) (0)203 2284312
Word count:
Abstract: 250
Article: 2252

Corresponding author:
Dr John Lally
PO63, Department of Psychosis Studies
Institute of Psychiatry, Psychology and Neuroscience (IoPPN),
King’s College London,
De Crespigny Park
London SE5 8AF
Email: john.lally@kcl.ac.uk
Tel: (0044) (0)203 2286000
Fax: (0044) (0)203 2284312

Acknowledgment and disclosures:
Only 2 authors (DT, FG) declare a potential conflict of interest, although not in relation to this work.

All other authors (JL, SM, AK, EW, RJF, AM and JHM) declare no conflict of interest

DT has the following declaration of interest. Advisory Board member for: Lundbeck, Servier, Sunovion; lectures for Janssen, Lundbeck, Otsuka, Servier: research funding from: BMS, Janssen, Lundbeck.. FG has received support or honoraria for CME, advisory work and lectures from Bristol-Myers Squibb, Janssen, Lundbeck, Otsuka, Roche, and Sunovion, has research funded by an NHS Innovations/Janssen-Cilag award and has a family member with professional links to Lilly and GSK, including shares. FG is in part funded by the National Institute for Health Research Collaboration for Leadership in Applied Health Research & Care Funding scheme and by the Stanley Medical Research Institute.

The other authors have no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; there are no other relationships or activities that could appear to have influenced the submitted work.

This paper represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS
Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Purpose/Background

Clozapine is associated with haematological abnormalities, with neutropenia and agranulocytosis of most concern. Granulocyte colony-stimulating factor (G-CSF) has been used to support clozapine rechallenge following neutropenia with the aim of maintaining the neutrophil count. This study aims to explore the practice, use, safety and efficacy of G-CSF in this context.

Methods/Procedures

We conducted a systematic review to identify all studies investigating or describing G-CSF as a prophylaxis to enable continued clozapine treatment during a rechallenge.

Findings/Results

We identified 32 reports of patients who received G-CSF either regularly (n = 23), or as required (n = 9) to support clozapine rechallenge following an episode of neutropenia necessitating discontinuation of clozapine. Seventy-five percent (n=24) of published cases remained on clozapine with the use of continual prophylactic G-CSF or after single G-CSF administrations (N=8). Seventy percent (n=16) of cases in receipt of continual prophylactic G-CSF were successfully maintained on clozapine. However, one of the three episodes of rechallenge in those with a history of severe agranulocytosis (ANC <0.1x10⁹/L) had a recurrence of agranulocytosis at week 9.

Implications/Conclusions
Our findings suggest that GCSF can sometimes be safely used to support the maintenance of normal neutrophil counts and clozapine use post-neutropenia. Publication bias is an important limitation, however. Also, few reports clearly documented the presence or absence of an independent non-clozapine cause of the index neutropenia, which may have increased success rates. Furthermore, adverse events were not systematically recorded. Prospective studies are needed to determine safety, as if agranulocytosis occurs on clozapine while supported by G-CSF, there is no obvious alternate rescue therapy to promote granulopoiesis. From the available data, it is not possible to recommend this course of action for someone with a true clozapine agranulocytosis.

**Keywords:** granulocyte colony stimulating factors; G-CSF; GM-CSF; treatment-resistant; schizophrenia; clozapine; neutropenia; agranulocytosis

**Introduction**

Clozapine remains the gold standard treatment for treatment resistant schizophrenia (TRS) (1) and is associated with clinical response in 50-60% of patients with TRS (2, 3) However, its use is restricted due to the risk of potentially life-threatening adverse events. (4) In particular, clozapine use has a risk of agranulocytosis, and in many countries, the emergence of neutropenia, which can presage agranulocytosis, means that clozapine must be discontinued.(5)

Rechallenge after clozapine associated neutropenia carries significant risk, especially following an episode of clozapine-associated agranulocytosis (CIA) where recurrence of neutropenia on rechallenge occurs in 80% of patients in contrast to 30% following a neutropenia-related discontinuation.(6) In an earlier retrospective case review, 38% of cases overall developed a neutropenia on clozapine rechallenge, and for 85% of these the neutropenia occurred more quickly and was more severe than during the first clozapine trial. Further, for 65% of the cases who developed a further neutropenia on rechallenge, the neutropenia was longer in duration than the original episode.(7)
More recently, granulocyte colony-stimulating factors (G-CSFs), and granulocyte-macrophage colony-stimulating factors (GM-CSFs) have been used in specialist centres with the aim of preventing the recurrence of neutropenia on clozapine rechallenge. However, this practice has not been systematically reviewed.

Therefore, in this study we aimed to synthesize the published data in order review the efficacy of G-CSF during clozapine rechallenge for the prevention of recurrence of clozapine associated neutropenia or agranulocytosis, to describe the dose and frequency of G-CSF used and to review adverse incidents.

**Methods**

We performed a systematic literature search to identify all published interventional and observational studies, case series and case reports, up until September 2016, investigating or describing G-CSF use as either a regular or as required (PRN) administrations, to support resumption and maintenance of clozapine treatment. We defined as required administrations as those cases in which there was an a priori plan to administer G-CSF in single or consecutive G-CSF doses in the event of a neutropenic episode (as defined by the individual case reports), and where G-CSF was discontinued upon neutrophil recovery. Regular administration was defined as regular use of prophylactic G-CSF; even where the neutrophil count was normal or high. This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) standard. (8)

**Inclusion criteria**

Studies were included in this systematic review if they included: (1) participants (no age restriction) who had a clozapine rechallenge after an episode of clozapine associated neutropenia; (2) participants who were treated prophylactically with regular G-CSF, or with as required administrations of G-CSF to enable continued clozapine use during rechallenge; and (3) were published in a peer reviewed journal.
Exclusion criteria

Studies were excluded if: (1) G-CSF was used to support the maintenance of clozapine treatment during chemotherapy; (2) if there were insufficient laboratory data to permit inclusion of the report and; (3) if G-CSF was not used to support continued clozapine use during a rechallenge.

Information sources and searches

Two independent reviewers (JL & SM) performed a search using Medline, EMBASE, Scopus and Google Scholar from inception until September 2016. The following search terms were used, both alone and in combinations: Granulocyte Colony-Stimulating Factor OR granulocyte-macrophage colony-stimulating OR GCSF OR G-CSF OR GMCSF OR GM-CSF AND clozapine OR clozaril OR denzapine OR zaponex OR leponex.

In addition, the reference lists of the retrieved articles and relevant review articles were examined for cross-references.

Study selection and exclusion

All abstracts meeting the criteria were obtained, and independently examined by the authors (JL and SM). The two appraisers applied the eligibility criteria to produce a list of full text articles. There was no search for unpublished works, although authors were contacted for clarification where necessary. Reference lists were searched for additional studies.

Primary outcome

The primary outcome was the continuation of clozapine with white cell and neutrophil count within the allowed ranges for continued clozapine prescription (i.e. WCC>3.0 x10^9/L and ANC>1.5x10^9/L) at the end of follow-up which was designated a “successful outcome”.

Secondary outcomes
Since filgrastim was the most common drug used, we examined for associations between the dose of filgrastim used and successful outcome. We recorded successful rechallenge rates for patients where the index episode was agranulocytosis (absolute neutrophil count <0.5 x10^9) or severe agranulocytosis (ANC < 0.1x10^9/L).

**Data extraction**

Articles included were critically reviewed by two authors (JL and SM) and the following information extracted where possible: age, gender, ethnicity, number of previous clozapine (re-)challenges, severity of initial neutropenia, G-CSF/GM-CSF dose, frequency and type of G-CSF used; duration of follow up; and successful outcome, defined as continuation of clozapine treatment or not, alternative causes of neutropenia, and adverse events. We did not undertake a risk of bias assessment of the included studies, as the majority were case series/reports.

**Results**

**Study selection, study and participant characteristics**

The study selection process, search results, and reasons for exclusion are given in figure 1.

The initial search yielded 766 references. After checking titles and abstracts, 57 full texts were screened. This selection process refined the number of relevant articles to 16 clinical reports, 6 of which were case series and 10 of which were case reports. No interventional or observational studies were identified.

We identified 32 episodes (in 31 patients) of clozapine re-challenge, where G-CSF was prescribed as maintenance prophylaxis (n=23)(9-19) or as single, as required administrations (n=9)(13, 14, 20-24) to enable continued clozapine treatment.

**Cause of the initial neutropenic episode**
An appraisal of potential alternative explanations for the initial neutropenia (e.g., viral illness, other drug treatments) was documented in 6 of the 32 cases. Four cases provided sufficient information to indicate that a ‘true’ clozapine induced neutropenia or agranulocytosis had occurred, (9, 17, 20, 24) while in two cases, other contributing factors were identified. (15, 19)

**G-CSF in clozapine rechallenge**

Twenty-three of the 32 cases identified received continual G-CSF as prophylaxis (mean duration of G-CSF use: 8.8 (4.2) months, median =11 months; range 1.25-13 months), while 9 received G-CSF as required (there were no cases reported where as required G-CSF was prescribed but not administered).

Seventy five percent (n=24) of cases remained on clozapine with the support of regular G-CSF (n=16) or after as-required G-CSF administrations (n=8) (mean duration of follow up: 11.8 (5.4) months, median =12 months; range 5-30 months), while in 25% (n=8) of cases clozapine was discontinued due to recurrence of neutropenia, or an attenuated response to G-CSF suggesting an enhanced risk of agranulocytosis leading to a clinician initiated discontinuation. Seventy percent (n=16) of cases in receipt of continual prophylactic G-CSF were successfully maintained on clozapine for an average follow up period of 10.9 (SD = 2.5) months (median 12 months; range 5-13 months). The mean time to clozapine discontinuation in those treated with continual G-CSF (n=6) was 3.0 (2.8) months (range =0.25-7 months). Seventy-eight percent were treated with filgrastim (n=25), 16% were treated with lenograstim (n=5) while the other two cases were treated with G-CSF (formulation not specified) and GM-CSF. Fifteen cases received G-CSF weekly and seven twice weekly, with two receiving filgrastim 480mcg daily. Seventy one percent of those treated with continual filgrastim (n=15) and 50% of those treated with continual lenograstim remained on clozapine (n=1). The characteristics of G-CSF use and associations with continued clozapine use are show in table 1.
Seventy-four per cent of cases where sex was specified were male (17 / 23), with 76% of white ethnicity (n=19) and 20% of black ethnicity (n=5). Eighty-four percent (n=16/19) of those of white ethnicity remained on clozapine compared to 60% (n=3/5) of those of black ethnicity.

**Previous neutropenic episode and outcomes during rechallenge**

Data were available for 17 of the cases regarding the degree of neutropenia at the index clozapine discontinuation, with seven cases having had agranulocytosis (ANC 0.1-0.5x10^9/L), three with severe agranulocytosis (ANC <0.1x10^9/L), while the other seven had neutropenia (ANC 0.5-1.5 x10^9/L). All those with a documented ANC < 0.5x10^9/L were prescribed continual G-CSF prophylaxis during rechallenge. Three from seven cases with a prior agranulocytosis failed rechallenge, as did one third (1/3) of those with a prior history of severe agranulocytosis. One case with an index episode of severe agranulocytosis had a recurrence of agranulocytosis (ANC =0.3x10^9/L), on a first rechallenge, while treated with G-CSF 300mcg twice weekly, subsequently had a second rechallenge, supported on G-CSF 480 mcg twice weekly, and was successfully maintained on clozapine at the time of follow up(12.5 months), (mean ANC, =15.8 x10^9/L; median ANC=10.5 x10^9/L; range ANC= 3.7 x10^9/L –51.3 x10^9). (17)

**Adverse events**

Only nine cases reported on adverse events relating to G-CSF use. Two had evidence of a rebound leucocytosis, (15, 20) while in another case, a mild subjective euphoria in the hours post G-CSF administration was reported.(9) The other six cases did not have any adverse events associated with G-CSF use. (13, 18, 22, 24)

**Discussion**

In this first systematic review of the use of G-CSF to support clozapine re-challenge and maintenance, it appears that G-CSF is an effective strategy for some people. Seventy-five
percent of cases were able to continue clozapine with the use of G-CSF, either as regular prophylaxis (70% success rate) or as required administrations (89% success rate).

Our review findings provide the largest synthesis of cases where G-CSF has been used to prevent recurrence of neutropenia and/or to allow for the continuation of clozapine. In the majority of published cases the use of G-CSF enabled clozapine to be continued for at least 10 months. This is in keeping with a recent systematic review, where clozapine rechallenge was successful in 78/112 patients (70 %) after neutropenia. We identified that 60% of those with an index episode of agranulocytosis had a successful outcome with continual G-CSF use, a higher figure than the 3/15 patients (20 %) with a successful rechallenge after agranulocytosis in the review of Manu et al. That same review examined 11 cases of rechallenge after neutropenia in which seven patients successfully continued clozapine while receiving G-CSF. Our review expands on this by identifying 32 episodes in which G-CSF was used to support clozapine rechallenge or clozapine continuation in cases where low neutrophil counts led to interruption of treatment.

Rechallenge after neutropenia or agranulocytosis is a risky enterprise and a complex clinical decision, especially as the long term consequences of maintenance G-CSF treatment in the absence of a primary haematological problem are unclear. Nevertheless, our findings suggest that, in some cases, G-CSF can be successfully used to facilitate the successful re-initiation and maintenance of clozapine, although there is insufficient data systematically examining adverse outcomes to be able to comment authoritatively on safety.

**Limitations**

Our findings must be viewed in relation to limitations in the primary study data. Only 6 of the reported cases provided an evaluation for non-clozapine related causes of the initial neutropenia event. This raises the possibility that some of the index events may not have been a true clozapine induced neutropenia, but neutropenia secondary to alternative non-clozapine factors, a commonly encountered scenario in specialist clinical practice. The risk
of neutropenia recurrence during clozapine rechallenge depends on whether the index event was truly caused by clozapine or not. The paucity of data relating to this important factor in the cases identified in this review, means that some of the cases reported may not represent true clozapine-induced neutropenia. Any non-clozapine related neutropenic and agranulocytosis episodes, may have contributed to the successful rechallenge, raising the possibility of an overestimation of the rate of successful rechallenge.

There were no controlled studies available, and there is a need for caution in interpreting data relating to case reports and case series.(25) Case reports alone cannot provide an accurate or quantitative measure of the risk for complications or death associated with a drug or treatment intervention such as this. A publication bias in favour of cases in which rechallenge was successful is probable. Furthermore, unreported deaths or severe adverse reactions may have occurred during the use of G-CSF. A prospective placebo controlled trial to establish the efficacy of G-CSF in clozapine rechallenge would be the gold standard approach to establish this, though the rarity of clozapine rechallenge may make such a study impractical outside highly specialised centres. As such, multicentre observational and retrospective studies to establish the efficacy of G-CSF in clozapine associated agranulocytosis would be the first choice for future research.

**Conclusions**

We provide further evidence that the use of G-CSF can support successful clozapine rechallenge after discontinuation because of an episode of neutropenia/agranulocytosis. However, given the paucity of systematically reported data on this topic and the reliance on case reports which may be subject to publication bias, these results should be interpreted with caution. From the available data, it is not possible to recommend this course of action for someone with a true clozapine agranulocytosis.


<table>
<thead>
<tr>
<th></th>
<th>All patients</th>
<th>Remained on clozapine</th>
<th>Clozapine discontinued</th>
<th>$X^2/T$ test; $p$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Remained on clozapine:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continual G-CSF, n (%)</td>
<td>23 (72)</td>
<td>24 (75%)</td>
<td>8 (25%)</td>
<td></td>
</tr>
<tr>
<td>G-CSF as required, n (%)</td>
<td>9 (28)</td>
<td>16 (70)</td>
<td>7 (30)</td>
<td></td>
</tr>
<tr>
<td><strong>G-CSF used:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Filgrastim, n (%)</td>
<td>25</td>
<td>19 (76)</td>
<td>6 (24)</td>
<td>0.545; 0.405</td>
</tr>
<tr>
<td>Lenograstim, n (%)</td>
<td>5</td>
<td>3 (60)</td>
<td>2 (40)</td>
<td></td>
</tr>
<tr>
<td><strong>Filgrastim mean (SD)</strong></td>
<td>680.4 (710.6)</td>
<td>504 (227.3)</td>
<td>450 (173.1)</td>
<td>0.434; 0.670</td>
</tr>
<tr>
<td>weekly dose mcg/week</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Filgrastim dose/week:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;300mcg/week, n (%)</td>
<td>11</td>
<td>9 (82)</td>
<td>2 (18)</td>
<td>0.683; 0.365</td>
</tr>
<tr>
<td>≤ 300mcg/week, n(%)</td>
<td>12</td>
<td>8 (67)</td>
<td>4 (33)</td>
<td></td>
</tr>
</tbody>
</table>
Fig. 1. Flow diagram of article search and review process

- Records identified through database searching (n = 766)
- Records after duplicates removed (n = 683)
- Studies included from database search (n = 52)
- Articles excluded at title/abstract level (n = 631)
- Potentially eligible articles identified via hand search (N = 5)
- Full-text articles assessed for eligibility (n = 57)
- Studies included in review (n = 16)

Exclusion (n = 41):
- Systematic review (n = 3)
- Inappropriate study population (n = 37)
- Incomplete data information (n = 1)
Dear Dr David J. Greenblatt, 5th May 2017

Editor in Chief,

Journal of Clinical Psychopharmacology,

RE: The use of G-CSF in clozapine rechallenge: a systematic review

Thank you for your email on the 28th April 2017 requesting a revision of the article ‘The use of G-CSF in clozapine rechallenge: a systematic review’, subsequent to the first review process. We have enclosed a revised version of this manuscript. We believe all of the reviewer’s concerns have been addressed in this version and we hope that it may now be accepted by the Journal of Clinical Psychopharmacology. We have retained our cautious approach regarding the use of G-CSF in clinical practice for clozapine rechallenge which is highlighted in our abstract and in the conclusion to our discussion.

This article is not currently under consideration for publication in another journal. The conflict of interest statement is complete within the electronic submission. All authors have contributed significantly; all authors are in agreement with the content of the manuscript. Below is our response to the reviewers’ comments.

We thank you for kindly considering our paper and hope to hear from you soon.

Best wishes,
Dr John Lally on behalf of all authors.

Ref.: Ms. No. JCP-D-17-00025
The use of GCSF in clozapine rechallenge: a systematic review

The Journal of Clinical Psychopharmacology

Dear Dr. Lally:

The Editors would like you to Revise your paper according to their comments and those of the 2 reviewers (See BELOW).

-------------------------------
Editors’ Comments to Address (required):
-------------------------------

We would like to reconsider a revised version of your manuscript. The reviewers had a number of observations that you will need to deal with as you work on the paper.

The Editors had the following additional points for revision.

We need to have the paper be much more circumspect about the strength of the data with respect to the drawing of definitive conclusions. As best we can tell, there are no controlled studies available. You are relying entirely on uncontrolled observations: case reports, case series, etc.

This amounts to pharmacovigilance data, which has huge limitations.

In this journal, we have presented a position on pharmacovigilance (2015; 35: 361-363), which you should cite and discuss.

The point is that you simply cannot draw any substantive conclusions about whether the use of G-CSF is or is not a reasonable approach to preventing or treating neutropenia associated with clozapine. Your revised manuscript will need to make this very clear.

Response: JL et al – We thank the editor for the opportunity to revise the manuscript in light of the reviewers comments.

We have modified the content to better reflect that we have not provided robust evidence for G-CSF use in clozapine rechallenge, in addition to the following which we provided in the original submission:

In our abstract we conclude with the following:” From the available data, it is not possible to recommend this course of action for someone with a true clozapine agranulocytosis."

We state the following in our discussion:
“Rechallenge after neutropenia or agranulocytosis is a risky enterprise and a complex clinical decision, especially as the long term consequences of maintenance G-CSF treatment in the absence of a primary haematological problem are unclear. Nevertheless, our findings suggest that, in some cases, G-CSF can be successfully used to facilitate the successful re-initiation and maintenance of clozapine, although there is insufficient data systematically examining adverse outcomes to be able to comment authoritatively on safety. “

And

“There were no controlled studies available, and there is a need for caution in interpreting data relating to case reports and case series.\(^{(27)}\) Case reports alone cannot provide an accurate or quantitative measure of the risk for complications or death associated with a drug or treatment intervention such as this. A publication bias in favour of cases in which rechallenge was successful is probable. Furthermore, unreported deaths or severe adverse reactions may have occurred during the use of G-CSF. A prospective placebo controlled trial to establish the efficacy of G-CSF in clozapine rechallenge would be the gold standard approach to establish this, though the rarity of clozapine rechallenge may make such a study impractical outside highly specialised centres. As such, multicentre observational and retrospective studies to establish the efficacy of G-CSF in clozapine associated agranulocytosis would be the first choice for future research.”

We have referenced the Greenbalt et al editorial at the beginning of this paragraph.

And in the conclusion we state the following:

“However, given the paucity of systematically reported data on this topic and the reliance on case reports which may be subject to publication bias, these results should be
interpreted with caution. From the available data, it is not possible to recommend this
course of action for someone with a true clozapine agranulocytosis.”

Journal Style Items to Address/Check (required):

1. Brief Report Format: A Brief Report should be no more than 14 double-spaced pages in total
   length including abstract, text, reference list, tables, and figures. Place each figure and/or table on
   a separate page, and EACH is counted as ONE Page. The title page is not counted. Number pages.

2. ABSTRACT: Include the abstract in the manuscript file AND also in the separate abstract box
   online.

   NOTE: Beginning January 2017, Abstracts must be in "structured abstract" format with specific
   headings as noted below.

   Abstract:
   Purpose/Background
   Methods/Procedures
   Findings/Results
   Implications/Conclusions.

3. Figures: Place each on a separate page at the end of the manuscript. Each figure must be
   labeled and include a legend either on the figure or on a separate page. Make sure figures pass
   the online art quality check for approved format before submitting a revision.

4. Reference List: Specific and General Items to Address/Check:

   - NOTE: Reference #21: Provide more information.

   - Double-space the entire list.
   - Please make sure that EACH reference is cited in the text In Order by number.
   - Each journal name must be abbreviated using approved “Index Medicus” style.
   - You only need the first 3 authors' names and then use “et al”.
   - NOTE: Provide inclusive page numbers (as 340-345).
   - Remove publication months/issue numbers.
   - Citations for "DSM" publications or package inserts should be cited in the text only with no
     number.

Cover Letter: When you submit your revised manuscript, include a cover letter explaining ALL the
changes made, responding in DETAIL to each item raised by the Editors and the Reviewers. The
revision cannot be re-evaluated if this information is missing.
NOTE: Please DO NOT highlight the changes or use track changes in the revised manuscript. We require a CLEAN Manuscript copy.

The files for the title page, manuscript, and tables must be submitted in WORD format. Number text pages.

No files should be loaded in the category "Supplemental Digital Content" unless the item is to be posted on the Journal website only.

To submit a revision, go to [https://emea01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fjcp.edmgr.com%2F&data=01%7C01%7Cjohn.lally%40kcl.ac.uk%7C01ca0d0b55fb444ed1df08d48e638f87%7C83370cf1416f34c16b83c724071654356%7C0&sa=bn3iwoWZbISBo5fMF3zvVpySDBmv7xklclHpJ667e%3D&reserved=0](https://emea01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fjcp.edmgr.com%2F&data=01%7C01%7Cjohn.lally%40kcl.ac.uk%7C01ca0d0b55fb444ed1df08d48e638f87%7C83370cf1416f34c16b83c724071654356%7C0&sa=bn3iwoWZbISBo5fMF3zvVpySDBmv7xklclHpJ667e%3D&reserved=0) and enter your login name and password, and Click on “Author”. On the Main Menu, click on "Submission Needing Revision,". There is no deadline for submitting revisions.

NOTE: Required Copyright/Author Disclosure Forms: EACH author must complete the online copyright/disclosure form (no signature is needed). See details on your online "Author Login"/Main Menu page and below.

(Note: Copyright forms from the "ICMJE" organization cannot be used.)

You are required to enter EACH coauthor’s correct Email address on the author names list when you submit your manuscript, and each author will receive an email with a link to access the online copyright form. Go to your Author Main Menu page to add/update email addresses. To check the status of your coauthors’ copyright forms, see the steps below:

1. Login to your author account.
2. Access this submission.
3. From the Action links, click the link for “Author Status.”
4. Click “Resend Letter” to any authors who have not yet completed the form or to “verify authorship”.

All relevant author disclosures/conflicts of interest and sources of funding/support must also be stated on the Title Page; OR indicate “The authors declare no conflicts of interest”.

----------------------

Note from the Publisher regarding OPEN ACCESS:

If you would like your submission, if accepted, to be open access, please complete the following steps. An information sheet is available at [https://emea01.safelinks.protection.outlook.com/?url=http%3A%2F%2Flinks.lww.com%2FLWW-ES%2FA48&data=01%7C01%7Cjohn.lally%40kcl.ac.uk%7C01ca0d0b55fb444ed1df08d48e638f87%7C83370cf1416f34c16b83c724071654356%7C0&sa=bn3iwoWZbISBo5fMF3zvVpySDBmv7xklclHpJ667e%3D&reserved=0](https://emea01.safelinks.protection.outlook.com/?url=http%3A%2F%2Flinks.lww.com%2FLWW-ES%2FA48&data=01%7C01%7Cjohn.lally%40kcl.ac.uk%7C01ca0d0b55fb444ed1df08d48e638f87%7C83370cf1416f34c16b83c724071654356%7C0&sa=bn3iwoWZbISBo5fMF3zvVpySDBmv7xklclHpJ667e%3D&reserved=0).

1. A License to Publish (LTP) form must be completed for your submission to be made open access. Please download the form
2. Upon acceptance of your submission, within your Acceptance decision letter will be a payment link to complete the open access process. The cost for publishing an article as open access can be found at https://emea01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fedmgr.ovid.com%2Fjcp%2Faccounts%2Fifauth.htm&data=01%7C01%7Cjohn.lally%40kcl.ac.uk%7C01ca0d0b55fb444ed1df08d48e638f87%7C8370cf1416f34c16b83c724071654356%7C0&sdata=t7mKKY%2Ba870C%3D&reserved=0. sign it, and submit the file as part of your revision (using the Attach Files submission step in Editorial Manager).

We look forward to seeing your revised manuscript. Thank you for submitting your work to the Journal of Clinical Psychopharmacology.

Sincerely,

David J. Greenblatt, M.D.
Editor-in-Chief

and

Ms. Barbara Kern, Managing Editor
The Journal of Clinical Psychopharmacology
Tufts University School of Medicine
Boston, MA 02111

Email: barbara.kern@tufts.edu

Comments of the 2 Reviewers:

Reviewer #1:

The only problem that I have with it is the following statement:

"There are no clear criteria for clozapine rechallenge where clozapine treatment is suspended following neutropenia,(25)".

If I am interpreting the recently enacted Clozapine REMS Program correctly, it states clear criteria for clozapine re-challenges.

Response: JL et al –We thank the reviewer for their expert comment. We agree that this statement is ambiguous, and in light of the recent clozapine REMs program is inaccurate in relation to neutropenia. We have now removed the statement from our discussion.

Reviewer #2:
This is a worthwhile contribution to the question of successful rechallenge with clozapine after neutropenia or agranulocytosis. However, I consider that it could be substantially shortened (to 50%) and that this would improve the message.

The substantial proportion of the data on page 7 (results) could be presented more helpfully in a table.

Response: JL et al: We thank the reviewer for highlighting this. We have included a table, in place of some of the results, specifically in relation to associations with G-CSF formulation and doses used and favourable outcomes. We hope that this is acceptable. A cost-effectiveness analysis would add value.

Response: JL et al. We agree with the reviewer that this would be an interesting addition to the study, but we have not sought to conduct such an analysis based on the data available to use in this review.

Page 4, adverse incidences should be adverse events or adverse incidents.

Page 7, 'or an attenuated response to G-CSF, which, although not breaching licensing requirements, suggested an enhanced risk of agranulocytosis leading to a clinician initiated discontinuation.' is a bit turgid. Mention of the licensing requirements doesn't help and isn't relevant.

JL et al –We have updated the manuscript in relation to both of the above points.

Page 9, 'In the majority of published cases the use of G-CSF enabled clozapine to be continued for at least 18 months.' The results indicate successful continuation for up to 13 months. Is this an error, or does it come from somewhere else or what? Please clarify.

JL et al –We thank the reviewer for noting this. This is an error and should read 10 months.

Page 10, 'Most patients with clozapine rechallenge are not reported in the literature..' you can’t make a statement like this without a reference. This is sufficient 'A publication bias in favour of cases in which [there is a favourable outcome] rechallenge was successful is probable.'

JL et al –We thank the reviewer for this suggestion and have updated as follows: “A publication bias in favour of cases in which rechallenge was successful is probable.”

Page 10, the last sentence is incomplete. Is a prospective placebo controlled trial a realistic expectation? Perhaps a system of canvassing psychiatric services for cases of rechallenge is a more likely option.

JL et al –We thank the reviewer for highlighting this omission. This is now corrected and reads as follows:
“A prospective placebo controlled trial to establish the efficacy of G-CSF in clozapine rechallenge would be the gold standard approach to establish this, though the rarity of clozapine rechallenge may make such a study impractical outside highly specialised centres. As such, multicentre observational and retrospective studies to establish the efficacy of G-CSF in clozapine associated agranulocytosis would be the first choice for future research.”

--

*JL et al* – We thank the expert reviewer for their comments that have improved the quality of our work.